Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors-Reference-Cited by-同舟云学术

Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors

Published:2019-01-28 Issue:4 Volume:62 Page:1781-1792
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Bagdanoff Jeffrey T.,Chen Zhouliang,Acker Michael,Chen Ying-Nan,Chan Homan,Dore Michael,Firestone Brant,Fodor Michelle,Fortanet Jorge,Hentemann Murphy,Kato Mitsunori,Koenig Robert,LaBonte Laura R.,Liu Shumei,Mohseni Movarid¹,Ntaganda Rukundo,Sarver Patrick,Smith Troy,Sendzik Martin,Stams Travis,Spence Stan,Towler Christopher¹,Wang Hongyun,Wang Ping,Williams Sarah L.,LaMarche Matthew J.^ORCID

Affiliation:

1. Chemical and Pharmaceutical Profiling, Novartis Pharmaceuticals, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01725

Reference50 articles.

1. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia

2. The tyrosine phosphatase Shp2 (PTPN11) in cancer

3. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors